Gujarat Kidney And Super Speciality Limited Approves FY26 Financial Results, Names New Auditors
Gujarat Kidney And Super Speciality Limited announced the approval of its audited financial results for the quarter and year ended March 31, 2026, following its Board of Directors meeting on May 28, 2026. The company also announced key appointments, including a new Internal Auditor and Secretarial Auditor, and confirmed plans for a special resolution meeting.The Board approved the audited standalone and consolidated financial results for the quarter and year ending March 31, 2026, along with the corresponding auditor's reports.
Governance and Operational Updates
During the board meeting, the management noted that the agenda item concerning the appointment of the CEO was deferred. Furthermore, the company confirmed it will conduct a postal ballot to seek special resolution approval for the variation in the Objects of the IPO.The board also ratified the appointment of professional auditors for the company’s governance structure:
- Internal Auditor: Mr. Siddharth Atulbhai Shah was appointed as the Internal Auditor for the Financial Year 2026-27. He is an Associate member of the Institute of Chartered Accountants of India (ICAI) with approximately 7 years of experience in Assurance, Internal Audit, IFC Forensic, and Fraud Risk.
- Secretarial Auditor: SPANJ & Associates was appointed as the Secretarial Auditors for five consecutive years, covering the period from 2026-27 to 2030-31, subject to the approval of the members.
Financial Performance Highlights
Gujarat Kidney And Super Speciality Limited provided detailed financial figures for the period ended March 31, 2026.Consolidated Financial Result (Rs. in Lacs)
The company reported significant growth in its consolidated financial performance for the year.
| Metric | Quarter Ended 31 March 2026 (Audited) | Quarter Ended 31 March 2025 (Audited) |
|---|---|---|
| Total Income | 8,288.60 | 4,039.70 |
| Total Expenses | 6,165.13 | 2,763.18 |
| Profit/(Loss) before tax | 2,123.47 | 1,276.52 |
| Total Tax expense | 442.28 | 326.58 |
| Profit/(Loss) after tax | 1,681.18 | 949.94 |
| Total Comprehensive Income | 1,678.22 | 980.86 |
| Basic Earnings per share | 2.49 | 1.85 |
Standalone Financial Result (Rs. in Lacs)
| Metric | Quarter Ended 31 March 2026 | Quarter Ended 31 March 2025 |
|---|---|---|
| Total Income | 4,059.47 | 3,528.11 |
| Total Expenses | 2,804.77 | 2,318.44 |
| Profit/(Loss) before tax | 1,254.70 | 1,209.67 |
| Total Tax expense | 264.56 | 298.77 |
| Profit/(Loss) after tax | 990.14 | 910.90 |
| Total Comprehensive Income | 999.26 | 921.13 |
| Basic Earnings per share | 1.59 | 1.79 |
Balance Sheet Comparison (Rs. in Lacs)
The company's total assets showed a substantial increase in the consolidated financials.
| Particulars | As at 31 March 2026 (Consolidated) | As at 31 March 2025 (Consolidated) |
|---|---|---|
| Total Assets | 29,764.00 | 5,534.47 |
| Total Equity | 25,251.22 | 2,593.61 |
| Total Liabilities | 4,290.45 | 2,821.83 |
In the standalone financial position, Total Assets stood at 26,607.67 Rs. in Lacs as of March 31, 2026, compared to 4,907.22 Rs. in Lacs on the same date the previous year.
Cash Flow Summary (Rs. in Lacs)
The consolidated cash flow statement indicated strong operational activity, though net cash from operating activities was negative for the year ended March 31, 2026.
| Metric | Year Ended 31 March 2026 | Year Ended 31 March 2025 |
|---|---|---|
| Net cash generated by operating activities | (386.17) | 1,360.80 |
| Net cash used in investing activities | (21,385.27) | (1,814.46) |
| Net cash used in financing activities | 22,840.08 | 616.21 |
| Cash and cash equivalents at the end of the year | 1,328.24 | 259.59 |
GKSL Stock Price Movement
On Wednesday, Gujarat Kidney And Super Speciality Limited shares slipped by 3.61% to settle at ₹135.98. The equity finished the session with a total traded volume of 317,229 shares.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.